Paros IBio's 'Lasmotinib' preclinical results published in research journal
Predicted impact: Low· Actual: −3.0% vs sector, volume 0.8× normal (5 trading days)
Preclinical research publication; no financial size or regulatory milestone disclosed.
388870 · KOSDAQ · ₩388870 · 파로스아이바이오
Predicted impact: Low· Actual: −3.0% vs sector, volume 0.8× normal (5 trading days)
Preclinical research publication; no financial size or regulatory milestone disclosed.
Also known as: Pharos iBio / 파로스아이바이오 / 388870 / KRX:388870
Source: KRX statistical information